Rapid generation of genetically engineered T cells for the treatment of virus-related cancers

Jinxing Jiang1, Ming Xia1, Lijie Zhang2

  • 1Cytotherapy Laboratory, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; the First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.

Cancer Science
|August 11, 2022
PubMed

Insights

Researchers developed a rapid workflow to generate human papillomavirus (HPV)-specific T cell receptor (TCR)-engineered T cells. This method identified a novel TCR targeting HPV16, demonstrating efficacy against cervical cancer cells and in preclinical models.

Area of Science:

  • Immunology
  • Oncology
  • Virology

Background:

  • Adoptive T cell therapy using T cell receptor (TCR)-engineered T cells targeting viral epitopes shows promise for virus-related cancers.
  • Efficient identification of viral epitopes and corresponding TCRs remains a significant challenge.

Purpose of the Study:

  • To develop and validate a workflow for the rapid generation of human papillomavirus (HPV)-specific TCR-engineered T cells.
  • To identify and characterize a novel TCR targeting HPV16 for potential therapeutic applications.

Main Methods:

  • Bioinformatic prediction of high-affinity epitopes for HLA-A11:01.
  • Cytotoxic T Lymphocyte (CTL) induction, Fluorescence-activated cell sorting (FACS), and next-generation sequencing for TCR clonotype determination.
  • Generation of a lentiviral vector library for TCRαβ pair validation and screening.

Main Results:

  • A workflow was established for rapid generation of HPV-specific TCR-T cells.
  • A TCR targeting the E692-101 epitope of HPV16 was identified and validated.
  • The identified HPV16-specific TCR-T cells demonstrated potent in vitro activity against HPV16-positive cervical cancer cells and suppressed tumor growth in vivo.

Conclusions:

  • The study provides a novel HPV16-specific TCR suitable for the HLA-A11:01 population.
  • The developed workflow enables efficient, large-scale screening of virus-specific TCRs for cancer immunotherapy.
  • This approach encourages further exploration of TCR-T cell therapy for virus-related cancers.

Related Concept Videos